Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of DKF-5122 vs AmBisome in Patients and Healthy Adults
NCT05749380Phase 1Completed
- Sponsor
- Dongkook Pharmaceutical
- Start
- Sep 2020
- Primary completion
- Jan 2022
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DKF-5122 in invasive fungal infection (IFI) and febrile neutropenia (FN) (4 arms), sponsored by Dongkook Pharmaceutical. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to Last Timepoint. Started Sep 2020; status: completed.
02
Drugs
DKF-5122
03
Conditions
invasive fungal infection (IFI)febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT05749380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05749380.